Safety, resource use, and quality of life in paramount: A phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 7, Issue 11, 2012, Pages 1713-1721

  Gridelli, Cesare ^a   De Marinis, Filippo ^b   Pujol, Jean Louis ^c   Reck, Martin ^d   Ramlau, Rodryg ^e   Parente, Barbara ^f   Pieters, Thierry ^g   Middleton, Gary ^h   Corral, Jesus ⁱ   Winfree, Katherine ^j   Melemed, Symantha ^j   Zimmermann, Anna ^j   John, William ^j   Beyrer, Julie ^j   Chouaki, Nadia ^j   Visseren Grul, Carla ^j   Paz Ares, Luis G ⁱ  

^a S G MOSCATI HOSPITAL   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

^d KRANKENHAUS GROSSHANSDORF   (Germany)

^e POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^f CENTRO HOSPITALAR DE VILA NOVA DE GAIA ESPINHO   (Portugal)

^g CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^h ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^j ELI LILLY AND COMPANY   (United States)

more..

Author keywords

EuroQol 5 dimensional questionnaire; Maintenance; Nonsquamous non small cell lung cancer; Pemetrexed; Quality of life

Indexed keywords

CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PEMETREXED; PLACEBO;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLOOD TRANSFUSION; CANCER FATIGUE; CANCER GROWTH; CANCER PAIN; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; EDEMA; EPIPHORA; EUROQOL 5 DIMENSIONAL QUESTIONNAIRE; FEMALE; HOSPITALIZATION; HUMAN; INDUCTION CHEMOTHERAPY; LETHARGY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALAISE; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PERFORMANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; STOMATITIS;

EID: 84867894352     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318267cf84     Document Type: Article

References (25)

1. Azzoli CG, Temin S, Aliff T, et al.; American Society of Clinical Oncology. 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol 2011;29:3825-3831.
2. Fidias PM, Dakhil SR, Lyss A P, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:591-598.
3. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440.
4. Cappuzzo F, Ciuleanu T, Stelmakh L, et al.; SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-529.
5. Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 1998;317:771-775.
6. Camps C, del Pozo N, Blasco A, Blasco P, Sirera R. Importance of quality of life in patients with non-small-cell lung cancer. Clin Lung Cancer 2009;10:83-90.
7. Hanna N, Shepherd FA, Fossella F V, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
8. Scagliotti G V, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
9. de Marinis F, Pereira JR, Fossella F, et al. Lung Cancer Symptom Scale outcomes in relation to standard effcacy measures: an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer. J Thorac Oncol 2008;3:30-36.
10. Belani C P, Brodowicz T, Ciuleanu TE, et al. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study. Lancet Oncol 2012;13:292-299.
11. Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012;13:247-255.
12. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
13. Fleming ID, Cooper JS, Hensen DE, et al, (Eds). Lung. AJCC Cancer Staging Manual, 5th Ed. Philadelphia, PA: Lippincott Williams & Wilkins, 1997. Pp.127-137.
14. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
16. Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Bethesda, MD: National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP); Published August 9, 2006. Available at: http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/ctc. htm#ctc-30. Accessed September 20, 2010.
17. Shaw J W, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005;43:203-220.
18. Rabin R, Oemar M, Oppe M; EuroQol Group. EQ-5D-3L User Guide: Basic information on how to use the EQ-5D-3L instrument. Version 4.0. April 2011. Rotterdam, Netherlands: EuroQol Group 2011. Available at: http://www.euroqol. org/eq-5d/publications/user-guide.html. Accessed September 20, 2010.
19. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-1108.
20. Pickard AS, Wilke CT, Lin H W, Lloyd A. Health utilities using the EQ-5D in studies of cancer. Pharmacoeconomics 2007;25:365-384.
21. Eguia B, Ruppert AM, Fillon J, et al. Skin toxicities compromise prolonged pemetrexed treatment. J Thorac Oncol 2011;6:2083-2089.
22. Glezerman IG, Pietanza MC, Miller V, Seshan S V. Kidney tubular toxicity of maintenance pemetrexed therapy. Am J Kidney Dis 2011;58:817-820.
23. Bharmal M, Thomas J 3rd. Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population. Value Health 2006;9:262-271.
24. Grieve R, Grishchenko M, Cairns J. SF-6D versus EQ-5D: reasons for differences in utility scores and impact on reported cost-utility. Eur J Health Econ 2009;10:15-23.
25. Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR. Cancer-related fatigue: the scale of the problem. Oncologist 2007;12 Suppl 1:4-10.